Epothilones are naturally occurring microtubule depolymerisation inhibitors, which stop the growth of human cancer cells in vitro at nano or even subnanomolar concentrations.
Epothilones, despite their promise as potent anti-cancer drugs, have encountered clinical difficulties due to their toxic side effects in patients.
Under the agreement, Insert Therapeutics will apply its proprietary Cyclosert transport system to select second generation epothilones now in development at R&D – a system designed to keep the drugs non-toxic until they actually reach the targeted tumor cells where active drug is released in a controlled fashion.
Find more details from the press release (a pdf file).
Comment Preview